Telbivudine versus lamivudine in Chinese
β
Jinlin Hou; You-Kuan Yin; Daozhen Xu; Deming Tan; Junqi Niu; Xiaqiu Zhou; Yuming
π
Article
π
2007
π
John Wiley and Sons
π
English
β 179 KB
Chronic hepatitis B and its life-threatening sequelae are highly prevalent in China. There is a need for effective new therapies to suppress hepatitis B virus (HBV) replication and ameliorate liver disease. In this study, we compared the efficacy of telbivudine, a nucleoside analogue, with lamivudin